Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization

Molecular Pharmaceutics

Volumn 10, Issue 8, 2013, Pages 2996-3004

  Primard, Charlotte ^a   Poecheim, Johanna ^a   Heuking, Simon ^a   Sublet, Emmanuelle ^a   Esmaeili, Farnaz ^a   Borchard, Gerrit ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

imiquimod; mucosal vaccine; PLGA nanoparticles

Indexed keywords

ANTIGEN; BOVINE SERUM ALBUMIN; CARBOXYMETHYL TRIMETHYL CHITOSAN; CHITOSAN DERIVATIVE; IMIQUIMOD; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; NANOPARTICLE; POLY(LACTIC CO GLYCOLIC ACID) BOVINE SERUM ALBUMIN IMIQUIMOD VACCINE; POLY(LACTIC CO GLYCOLIC ACID) BOVINE SERUM ALBUMIN VACCINE; POLYGLACTIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; FEMALE; HUMORAL IMMUNITY; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; MUCOSA; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS; CELL SURVIVAL; FEMALE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMMUNITY, MUCOSAL; IMMUNOLOGIC FACTORS; LACTIC ACID; MICE; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84881356899     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400092y     Document Type: Article

References (26)

1. Chadwick, S.; Kriegel, C.; Amiji, M. Nanotechnology solutions for mucosal immunization Adv. Drug Delivery Rev. 2010, 62, 394-407
2. Lee, S. W.; Markham, P. F.; Coppo, M. J.; Legione, A. R.; Markham, J. F.; Noormohammadi, A. H.; Browning, G. F.; Ficorilli, N.; Hartley, C. A.; Devlin, J. M. Attenuated vaccines can recombine to form virulent field viruses Science 2012, 337, 188
3. Gilbert, S. C. T-cell-inducing vaccines: what's the future Immunology 2012, 135, 19-26
4. Sharma, S.; Mukkur, T. K.; Benson, H. A.; Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems J. Pharm. Sci. 2009, 98, 812-843
5. Schwarz, K.; Storni, T.; Manolova, V.; Didierlaurent, A.; Sirard, J. C.; Rothlisberger, P.; Bachmann, M. F. Role of Toll-like receptors in costimulating cytotoxic T cell responses Eur. J. Immunol. 2003, 33, 1465-1470
6. Pawar, D.; Goyal, A. K.; Mangal, S.; Mishra, N.; Vaidya, B.; Tiwari, S.; Jain, A. K.; Vyas, S. P. Evaluation of mucoadhesive PLGA microparticles for nasal immunization AAPS J. 2010, 12, 130-137
7. Hagenaars, N.; Mania, M.; de Jong, P.; Que, I.; Nieuwland, R.; Slutter, B.; Glansbeek, H.; Heldens, J.; van den Bosch, H.; Lowik, C.; Kaijzel, E.; Mastrobattista, E.; Jiskoot, W. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine J. Controlled Release 2010, 144, 17-24
8. Mathot, F.; des Rieux, A.; Arien, A.; Schneider, Y. J.; Brewster, M.; Preat, V. Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier J. Controlled Release 2007, 124, 134-143
9. Akira, S.; Hemmi, H. Recognition of pathogen-associated molecular patterns by TLR family Immunol. Lett. 2003, 85, 85-95
10. Wagner, T. L.; Ahonen, C. L.; Couture, A. M.; Gibson, S. J.; Miller, R. L.; Smith, R. M.; Reiter, M. J.; Vasilakos, J. P.; Tomai, M. A. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod Cell Immunol. 1999, 191, 10-19
11. Vasilakos, J. P.; Smith, R. M.; Gibson, S. J.; Lindh, J. M.; Pederson, L. K.; Reiter, M. J.; Smith, M. H.; Tomai, M. A. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN Cell Immunol. 2000, 204, 64-74
12. Xirakia, C.; Koltsida, O.; Stavropoulos, A.; Thanassopoulou, A.; Aidinis, V.; Sideras, P.; Andreakos, E. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma Am. J. Respir. Crit. Care Med. 2010, 181, 1207-1216
13. Pockros, P. J.; Guyader, D.; Patton, H.; Tong, M. J.; Wright, T.; McHutchison, J. G.; Meng, T. C. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies J Hepatol. 2007, 47, 174-182
14. Heuking, S.; Iannitelli, A.; Di Stefano, A.; Borchard, G. Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination Int. J. Pharm. 2009, 381, 97-105
15. Astete, C. E.; Sabliov, C. M. Synthesis and characterization of PLGA nanoparticles J. Biomater. Sci., Polym. Ed. 2006, 17, 247-289
16. Slutter, B.; Plapied, L.; Fievez, V.; Sande, M. A.; des Rieux, A.; Schneider, Y. J.; Van Riet, E.; Jiskoot, W.; Preat, V. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination J. Controlled Release 2009, 138, 113-21
17. Messai, I.; Delair, T. Cationic biodegradable particles: Comparison of one or two step processes Colloids Surf., A. 2006, 278, 188-196
18. Jung, T.; Kamm, W.; Breitenbach, A.; Hungerer, K. D.; Hundt, E.; Kissel, T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide- co -glycolide): evaluation of antibody response after oral and nasal application in mice Pharm. Res. 2001, 18, 352-360
19. Holmgren, J.; Czerkinsky, C. Mucosal immunity and vaccines Nat. Med. 2005, 11, S45-S53
20. Chosidow, O.; Dummer, R. Imiquimod: mode of action and therapeutic potential Acta Derm.-Venereol., Suppl. 2003, 8-11
21. Camateros, P.; Tamaoka, M.; Hassan, M.; Marino, R.; Moisan, J.; Marion, D.; Guiot, M. C.; Martin, J. G.; Radzioch, D. Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463 Am. J. Respir. Crit. Care Med. 2007, 175, 1241-1249
22. Duechs, M. J.; Hahn, C.; Benediktus, E.; Werner-Klein, M.; Braun, A.; Hoymann, H. G.; Gantner, F.; Erb, K. J. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways Pulm. Pharmacol. Ther. 2011, 24, 203-214
23. Gill, M. A. The role of dendritic cells in asthma J. Allergy Clin. Immunol. 2012, 129, 889-901
24. Davidson, S.; Kaiko, G.; Loh, Z.; Lalwani, A.; Zhang, V.; Spann, K.; Foo, S. Y.; Hansbro, N.; Uematsu, S.; Akira, S.; Matthaei, K. I.; Rosenberg, H. F.; Foster, P. S.; Phipps, S. Plasmacytoid dendritic cells promote host defense against acute pneumovirus infection via the TLR7-MyD88-dependent signaling pathway J. Immunol. 2011, 186, 5938-5948
25. Nakano, H.; Burgents, J. E.; Nakano, K.; Whitehead, G. S.; Cheong, C.; Bortner, C. D.; Cook, D. N. Migratory properties of pulmonary dendritic cells are determined by their developmental lineage Mucosal Immunol. 2012, 6, 678-691
26. Tomai, M. A.; Vasilakos, J. P. TLR-7 and -8 agonists as vaccine adjuvants Expert Rev. Vaccines 2011, 10, 405-407